In this regard, in 2016, the specific BCL-2 inhibitor venetoclax (ABT-199), was approved by the Food and Drug Administration (FDA) for relapsed Chronic lymphocytic leukemia (CLL) with 17p deletion. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.